Response rates (Confirmed/unconfirmed with ≥16 weeks follow-up)
| Overall population | EGFR/ALK wild-type population | |||||||
|---|---|---|---|---|---|---|---|---|
| All cohorts | Combined cohort: D10–20 q4w or q2w + T1 | All cohorts | Combined cohort: D10–20 q4w or q2w + T1 | |||||
| n/N (%) | 95% CI | n/N (%) | 95% CI | n/N (%) | 95% CI | n/N (%) | 95% CI | |
| All patients | 21/84 (25) | 16–36 | 11/39 (28) | 15–45 | 21/73 (29) | 19–41 | 11/34 (32) | 17–51 |
| PD-L1+ (≥25%) | 7/20 (35) | 15–59 | 3/9 (33) | 8–70 | 7/17 (41) | 18–67 | 3/9 (33) | 8–70 |
| PD-L1- (<25%) | 11/49 (22) | 12–37 | 6/23 (26) | 10–48 | 11/45 (24) | 13–40 | 6/19 (32) | 13–57 |
| PD-L1- (0%) | 9/27 (33) | 17–54 | 6/12 (50) | 21–79 | 9/26 (35) | 17–56 | 6/11 (55) | 23–83 |
| All 2L patients | 15/32 (47) | 29–65 | 7/16 (44) | 20–70 | 15/31 (48) | 30–67 | 7/15 (47) | 21–73 |
| PD-L1+ (≥25%) | 6/8 (75) | 35–97 | 2/3 (67) | 9–99 | 6/8 (75) | 35–97 | 2/3 (67) | 9–99 |
| PD-L1- (<25%) | 7/18 (39) | 17–64 | 4/11 (36) | 11–69 | 7/17 (41) | 18–67 | 4/10 (40) | 12–74 |
| PD-L1- (0%) | 6/8 (75) | 35–97 | 4/5 (80) | 28–100 | 6/8 (75) | 35–97 | 4/5 (80) | 28–100 |
2L, second line: 1 prior line of therapy, receiving D+T in second line